Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CD161 monoclonal antibody IMT-009

An Fc-attenuated human immunoglobulin G1 (IgG1) monoclonal antibody directed against the C-type lectin-like receptor cluster of differentiation 161 (CD161), with potential immunomodulatory and antineoplastic activities. Upon administration, anti-CD161 monoclonal antibody IMT-009 selectivity targets, binds to and blocks CD161. This disrupts the interaction of CD161 with its ligand lectin-like transcript-1 (CLEC2D; LLT1; OCIL), prevents CD161-mediated signaling, abrogates the CLEC2D/ CD161-mediated suppression of CD161-positive T and natural killer (NK) cells, and restores the activation of effector functions of both CD161-positive T and NK cells against tumor cells, thereby enhancing cytotoxicity towards tumor cells. CD161, an inhibitory immune checkpoint, is broadly expressed on NK and a subset of memory CD4+ and CD8+ T cells. It plays a key role in cancer immune surveillance and its expression is associated with many types of cancer. CLEC2D is expressed on the surface of both malignant cells and immune cells, including activated B cells and myeloid cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:IMT 009
IMT-009
IMT009
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search